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Edited by Angel NebredaAbstract One prime candidate linking N-methyl-D-aspartate
(NMDA) receptors to the regulation of the MAP kinase cascade
is SynGAP, a negative regulator of Ras. In order to assess how a
physiological stimulus can alter SynGAP activity, an appropri-
ate whole cell system must be used and SynGAP must be specif-
ically extracted from membranes whilst preserving the catalytic
activity of the protein. Here, we have achieved this and studied
the eﬀect of NMDA/a-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA) and kainate receptor stimulations on
SynGAP activity in cortical neurones. Furthermore, we have
examined the role of extracellular Ca2+, CaM kinase II and
the PSD-95-NR2B subunit interaction in SynGAP activity reg-
ulation and propose a novel convergence of signalling between
AMPA, kainate and NMDA receptors.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Glutamatergic synapses are critical for excitatory synaptic
transmission in the CNS. They are believed to play a crucial
role in learning, memory and neuronal development processes
[1]. Excitatory synapses contain two classes of glutamate
receptors: metabotropic and ionotropic receptors. It is the
ionotropic, a-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA) and N-methyl-D-aspartate (NMDA), receptors
that are speciﬁcally implicated as molecular components medi-
ating neuronal development and synaptic plasticity [2,3]. In or-
der to understand the underlying mechanisms by which these
processes occur, it is important to investigate further the
molecular components in the post synaptic density (PSD) frac-
tion where these receptors are located and to identify the phys-
iological roles played by the proteins co-complexing with theseAbbreviations: PBS, phosphate-buﬀered saline; GAP, GTPase activat-
ing protein; NMDA, N-methyl-D-aspartate; AMPA, a-amino-3-hy-
droxy-5-methylisoxazole-4-propionic acid; APV, D()-2-amino-5-
phosphono-pentanoic acid; SDS, sodium dodecylsulphate; PSD, post
synaptic density
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that has recently been identiﬁed is the Ras regulatory protein
SynGAP [4,5]. This protein has been shown to be concentrated
in excitatory synapses and directly interacts with the PSD pro-
tein, PSD-95 [4,5]. NMDA receptors and the Ras/MAPK cas-
cade have been shown to be important in synaptic plasticity in
a range of organisms [6–8] and this signalling pathway has
been shown to be important in LTP; an apparent measure of
synaptic plasticity [9–11]. Hence, it has been proposed that
SynGAP could be a crucial signalling link between the NMDA
receptor and induction and/or maintenance of synaptic plastic-
ity [12]. Furthermore, SynGAP knock out studies have shown
that SynGAP plays a critical role in neuronal development,
induction of LTP, synapse formation and regulation of neuro-
nal apoptosis [13–17]. Thus, whilst there is considerable evi-
dence for the physiological function of SynGAP, there is still
very little known about the cellular mechanisms regulating
the activity of this important protein.
Previous work has shown that SynGAP is phosphorylated
by CaM kinase II [18–20] and in vitro studies have shown
that this phosphorylation increases the catalytic activity of
SynGAP [21] . In addition, PSD-95 has been shown to pro-
mote this CaM kinase II dependent phosphorylation [22].
Whilst phosphorylation site mapping conﬁrms that this phos-
phorylation does indeed occur in vivo, [21] the SynGAP
activity assessment studies have so far only been performed
on either recombinant SynGAP protein or on PSD prepara-
tions [21,23]. In order to assess more directly the eﬀect a
physiological stimulus has on SynGAP activity regulation,
an appropriate cellular system must be used and SynGAP
speciﬁcally extracted from membranes whilst preserving the
catalytic activity of the protein. Here, we have successfully
achieved this and using our assay system we have studied
the eﬀect ionotropic glutamate receptor stimulation has on
SynGAP catalytic activity in neurones. Furthermore, we have
studied the roles played by Ca2+, CaM kinase II and PSD-95
in these receptor triggered SynGAP activity regulation pro-
cesses. Our results conﬁrm some in vitro ﬁndings, modifying
other assumptions made and demonstrate a novel conver-
gence of signalling pathways between AMPA, kainate and
NMDA receptors.2. Materials and methods
2.1. Cortical neurone preparation
Neuronal cultures were prepared from 6- to 8-day-old Sprague–
Dawley rats as previously described [24]. Cells were used after 14–19
days in culture.blished by Elsevier B.V. All rights reserved.
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Adherent cells were gently washed with phosphate-buﬀered saline
(PBS) and incubated at 25 C for 5 min in extracellular buﬀer con-
taining 150 mM NaCl, 2.5 mM KCl, 10 mM Hepes (pH 7.5),
10 mM glucose, 5 mM EGTA and appropriate receptor agonists in
the presence or absence of free Ca2+ concentrations as indicated.
Cells were then washed with ice cold PBS and harvested by scraping
in ice cold lysis buﬀer containing 20 mM Tris (pH 7.5), 1% (v/v) terg-
itol, 0.1% (w/v) sodium dodecylsulphate (SDS), 0.5 mM DTT,
100 mM NaCl, 1 mM MgCl2, 50 lg/ml leupeptin, 10 lg/ml aprotinin,
0.5 mM PMSF and 0.2 mM Na3VO4. Cell lysates were homogenised
on ice and then centrifuged at 2000 · gav for 5 min. Supernatants
were collected for protein determination prior to SynGAP immuno-
precipitation.2.3. SynGAP immunoprecipitation and activity assay
Cell lysates (100 lg solubilised protein) were incubated at 4 C for
1.5 h with 1 lg anti-SynGAP antibodies (UBI) pre-conjugated to
100 ll 20% (v/v) protein A sepaharose beads. Immune complexes were
then washed three times with lysis buﬀer followed by gentle resuspen-
sion in 50 ll assay mix containing 25 mM Tris (pH 7.5), 6.25 mM
MgCl2, 1 mM DTT, 625 lM GTP, 1.25 mg/ml BSA and 0.06% (v/v)
NP-40. 1 lg recombinant GST H-Ras (UBI) was pre-loaded with
[c-32P] GTP by incubation at 30 C for exactly 10 min with 5 mCi
[c-32P] GTP (3000 Ci/mmol) in 20 mM Tris, pH 7.5 containing 5 mM
EDTA. After loading, 0.1 lg of Ras mix was added to each SynGAP
immunoprecipitation sample and incubated at 25 C for exactly
10 min. Reactions were stopped with ice cold stop buﬀer containing
25 mM Tris (pH 7.5), 0.1 M NaCl and 5 mM MgCl2 and immediately
ﬁltered through 25 mM nitrocellulose ﬁlters under vacuum. Filters
were washed three times with stop buﬀer before drying under vacuum
and scintillation counting.
Quantiﬁcation of SynGAP immunoprecipitated for GTPase activat-
ing protein (GAP) assays was undertaken using a modiﬁed Western
blot probing procedure. Essentially, 50% of the SynGAP immunopre-
cipitate sample was subjected to SDS–PAGE, Western blotted, incu-
bated with anti-SynGAP antibodies, followed by incubation with
mouse anti-rabbit biotinylated secondary antibodies and anti-avidin
HRP probing. The HRP activity was detected using a highly sensitive
enhanced chemiluminescence detection kit (‘‘Visualizer Western Blot
Detection Kit; U.B.I.) and images captured on BioMax XAR pre-
ﬂashed ﬁlm.2.4. Peptide sequences and loading of cells
All peptides used were synthesised at a purity of between 89% and
97% and were HPLC analysed (Sigma-Genosys). All peptides con-
tained N-terminal ﬂuorescein modiﬁcation.
PeptideP1
RRRRRRRRRRR
Peptide P2
RRRRRRRRRRRYEKLSSIESDV
Peptide P3
RRRRRRRRRRRYKKMPSIESDV
Peptide P4
RRRRRRRRRRRYEKLSSI
Peptide P5
RRRRRRRRRRRESDV
For peptide loadings, cells were incubated with peptides (2.5 lM) in
culture media at 37 C for 2–2.5 h prior to treatments and
harvesting.2.5. Solubilisation of cell membranes, co-immunoprecipitations and
Western blotting
Cells were scraped into Tris–HCl (pH 9), homogenised on ice and
then centrifuged at 20000 · gav for 30 min. The membrane pellet was
collected and resuspended in Tris–HCl (pH 9) at a ﬁnal protein con-
centration of 1 mg/ml. Membrane proteins (100 lg) were solubilised
in Tris–HCl (pH 9) containing 1 mM DTT, 1% (w/v) sodium deoxy-
cholate, 1% (v/v) Triton X-100, 1% (w/v) SDS and 1 mM PMSF. After
centrifugation of samples for 10 min at 100000 · gav, the supernatants
were collected, diluted 1:10 in RIPA buﬀer and then used for co-immu-
noprecipitation studies.Immunoprecipitations and Western blotting procedures were under-
taken as previously described by us [25]. Suppliers of antibodies were
as follows: anti-PSD95 antibodies (Abcam), anti-NR2 antibodies
(Invitrogen) and anti-SynGAP antibodies (U.B.I).
2.6. Estimation of free Ca2+ concentration in buﬀers
Free calcium concentrations in EGTA buﬀers were calculated using
the Eqcal software program (Biosoft).3. Results and discussion
The ﬁrst aim of our study was to establish conditions under
which we could extract suﬃcient amounts of SynGAP from
cultured cortical neurones, whilst preserving its catalytic activ-
ity, in order to undertake an in vitro Ras GAP assay. This is
important because whilst recombinant SynGAP activity assays
in vitro provide important information about potential regula-
tory mechanisms, they are not able to directly assess what is
happening in an intact cell system in response to an external
stimulus. Similarly, preparing PSD fractions for GAP assay,
after cellular stimulation, provides further information about
potential regulatory mechanisms but only allows the assess-
ment of total Ras GAP activities since they do not speciﬁcally
isolate SynGAP prior to in vitro activity assay. Hence, because
the NMDA receptor–PSD protein complex is known to be
tightly associated with the membrane [26], a harsh cocktail
of detergents in a high pH buﬀer is usually used for SynGAP
extraction [4]. We began by trying a number of detergent con-
ditions and found that by using a lysis buﬀer containing low
(0.1%) SDS and the non-ionic detergent tergitol (1%), without
the need of high pH conditions, we could successfully extract
approximately 50% of SynGAP from cells (Fig. 1A) and still
detect basal SynGAP stimulated Ras GTP hydrolysis
(Fig. 1B).
Next, we looked to see if we could stimulate NMDA recep-
tors and regulate SynGAP activity (Fig. 2). Using aspartate, a
selective agonist of the NMDA receptor [27,28], in the pres-
ence of its co-activator glycine [27,28] we were successfully able
to elevate the basal SynGAP activity by 38 ± 5% . This eﬀect
was blocked by magnesium (Fig. 2A), an eﬀect which is phys-
iologically characteristic of NMDA receptors [27]. In addition,
since removal of extracellular Ca2+ was also observed to block
aspartate-dependent SynGAP activation (Fig. 2A.), we further
studied the Ca2+ dependence of this receptor triggered Syn-
GAP activation (Fig. 2B). In vitro studies have demonstrated
a Ca2+ dependent, CaM kinase II mediated mechanism of Syn-
GAP activation. However, in these in studies very high calcium
concentrations (0.7 mM) are used to activate the kinase [21].
So, by EGTA buﬀering the extracellular Ca2+ concentration
we determined the eﬀect of extracellular free Ca2+ concentra-
tion on NMDA receptor activation of SynGAP (Fig. 2B).
We observed that NMDA receptor activation of SynGAP
was maximally achieved when extracellular free Ca2+ was at
a concentration between 30 and 100 lM and we estimated an
EC50 value for this eﬀect to be approximately 5 lM. These
Ca2+ concentrations would be well within the expected physi-
ological range at post synaptic membranes, where SynGAP
has been found. To test whether this Ca2+ dependence of Syn-
GAP activation is indeed mediated by CaM kinase II we pre-
treated cells with the selective inhibitor KN-62 [29]. We were
able to block the Ca2+ dependent NMDA receptor activation
of SynGAP with this drug (Fig. 2C). Thus, using our assay
Fig. 1. Solubilisation and assay of SynGAP from cortical neuronal
membranes. (A) Pellets, SynGAP remaining in membrane after
solubilisation; I.P.s, SynGAP immunoprecipitated from supernatant
fraction. Lanes 1 and 3, solubilisation using conditions for SynGAP
assay; lanes 2 and 4, solubilisation using conditions for co-immuno-
precipitation studies. (B) Assay of SynGAP activity. Cell lysates were
immunoprecipitated with (SynGAP) or without (control) the inclusion
of anti-SynGAP antibodies followed by Ras GAP assay (n = 3).
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tion of the NMDA receptor can stimulate SynGAP activity in
a Ca2+/CaM kinase II dependent manner.
As a negative control we next incubated neuronal cultures
with the competitive NMDA receptor antagonist D()-2-ami-
no-5-phosphono-pentanoic acid (APV) [27]. However, to our
surprise, we found that this ligand actually stimulated Syn-
GAP activity (Fig. 3A). In addition, this stimulation, unlike
that triggered by aspartate, was not signiﬁcantly altered byFig. 2. Eﬀect of NMDA receptor activation on SynGAP activity in
cortical neurones. Adherent cells in culture were treated at 25 C for
5 min with 100 lM aspartate and 3 lM glycine in extracellular
incubation buﬀer containing 1 mMMg2+ and 100 lM free Ca2+ (unless
otherwise indicated). Cells were then lysed, immunoprecipitated with
anti-SynGAP antibodies and assayed for Ras GAP activity as detailed
in Section 2. (A) Eﬀect of extracellular Mg2+ and Ca2+ on NMDA
receptor mediated SynGAP activation (n = 4). (B) Extracellular Ca2+
dose response curve for NMDA receptor mediated SynGAP activation
in the absence of Mg2+ (n = 8). (C) Eﬀect of pre-treating cells with
10 lMKN-62 on NMDA receptor mediated SynGAP activation in the
absence of Mg2+ and the presence of 100 lM free Ca2+(n = 4). Data
shown is representative of mean ± S.E.M values, n = number of
experiments performed on independent cell culture batches. Panel
inserts show SynGAP immunoprecipitates representative of a batch of
cells assayed. Panel A: lane 1, unstimulated; lane 2, Asp + Mg2+ + Ca2+;
lane 3, Asp Mg2+ + Ca2+; lane 4, Asp Mg2+  Ca2+. Panel C: lane
1, KN-62; lane 2, +KN-62 treated cells.
c
Fig. 3. Eﬀect of the NMDA receptor antagonist, APV, on SynGAP
activity in cortical neurones. Adherent cells in culture were treated at
25 C for 5 min with 5 lM APV in extracellular incubation buﬀer in
the presence or absence of 100 lM free Ca2+ as indicated. After
treatment, cells were lysed, immunoprecipitated with anti-SynGAP
antibodies and assayed for Ras GAP activity as detailed in Section 2.
Data shown is representative of mean ± S.E.M values for n = 4
experiments performed on independent cell culture batches. Panel
inserts show SynGAP immunoprecipitates representative of a batch of
cells assayed. Panel A: lane 1, unstimulated; lane 2, APV-Ca2+; lane 3,
APV + Ca2+; lane 4, APV + Ca2+ + KN-62 treated cells. Panel B: lane
1, unstimulated; lane 2, APV; lane3, Asp; lane 4, APV + Asp
stimulated cells.
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SynGAP activation with or without Ca2+, respectively). Fur-
thermore, the CaM kinase inhibitor KN-62 had no eﬀect upon
this APV triggered activation of SynGAP (42 ± 4% stimula-
tion after inhibitor treatment of cells). This eﬀect of a supposed
receptor antagonist was highly reproducible and the levels of
SynGAP activation were comparable to those observed with
the receptor agonist (Fig. 2). So our data is consistent with thisreceptor ligand being a biological agonist in that it has post
receptor eﬀects and the classiﬁcation of this drug as an antag-
onist was originally based on electrophysiological recordings
which only reﬂect its inability to open the Ca2+ ion channel
of the NMDA receptor. So, based on our observations we
would suggest that APV upon binding to the NMDA receptor
NR2 subunit, causes a conformational change which elicits a
post-receptor biological eﬀect (i.e., SynGAP activation). Thus,
we have evidence to support both a Ca2+-dependent and a
Ca2+-independent mechanism of NMDA receptor activation
of SynGAP. Furthermore, this ﬁnding is very interesting in
that others have shown diﬀerential eﬀects on LTD and LTP
using this NMDA receptor ‘‘antagonist’’ [30]. We suggest that
maybe these diﬀerential eﬀects are related to discrete biological
post receptor eﬀects of this drug. Thus, by using this drug it
may be possible to examine in isolation Ca2+ inﬂux and Syn-
GAP-dependent events.
To examine this further, we looked to see if APV and Aspar-
tate activation of SynGAP was additive. Triggering SynGAP
activation with these receptor ligands under conditions where
Aspartate activation of NMDA receptors is optimised (i.e.,
in the presence of glycine and extracellular Ca2+) we found
that these two ligands were indeed additive with respect to
SynGAP activation (Fig. 3B). Alone APV activated SynGAP
by 29 ± 2%, Aspartate activated SynGAP by 36 ± 4% and
when these ligands were incubated together SynGAP was acti-
vated by 67 ± 2%. Hence, this ﬁnding provides further evi-
dence that NMDA receptors are involved in two
independent SynGAP activation pathways and is consistent
with APV acting as a partial agonist.
Next, we reasoned that if APV was causing NMDA receptor
conformational changes then, most probably, these would
aﬀect interactions between the receptor subunits and co-
complexed signalling proteins. So, by disrupting receptor–
signalling protein interactions we could probe further the
molecular mechanisms required for each receptor ligand eﬀect.
One prime candidate for coupling SynGAP to the NR2 sub-
unit of the NMDA receptor is the PSD protein PSD95. It is
conceivable that SynGAP associates with the NMDA receptor
via interaction with PSD95. Indeed, the C-terminal (QTRV)
sequence found in SynGAP has been shown to interact directly
with PSD-95 [4] and, in turn, PSD-95 interacts with the PDZ-
binding motif (ESDV) located within the C-terminal region of
the NR2 subunit [31,32,35]. In cortical neurones, both NR2A
and NR2B subunits are believed to be expressed and associ-
ated with NR1 NMDA receptor subunits [33]. In common
with the NR2B subunit, the NR2A subunit C-terminus also
contains the ESDV motif . So, in order to disrupt the interac-
tion of PSD95 with NR2 NMDA subunits we synthesised pep-
tides containing an N-terminal ﬂuorescein tag followed by an
11 arginine (R11) protein transduction domain (which has been
shown to allow the passage of peptides into cells) [34,35] and
selective amino acid sequences corresponding to the NR2A
and NR2B C-termini. These peptides were loaded into neuro-
nes as previously described [34,35] and loading eﬃciency as-
sessed by ﬂuorescence microscopic detection of the
ﬂuorescein tag. Under our loading conditions, 90–100% of
adherent cells were routinely loaded with each peptide (data
not shown). The eﬀect of each peptide on aspartate (Ca2+-
CaM kinase II dependent) triggered activation of SynGAP
was then studied (Fig. 4A). From these studies, we found that
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the ﬂourescein tag and the R11 protein transduction domain,
was able to stimulate SynGAP to a similar extent as cells that
were not peptide loaded (41 ± 9% and 53 ± 2% for peptide P1
and no peptide, respectively); indicating that the cellular load-
ing of the tagged peptides did not interfere with the receptor–Fig. 4. Eﬀect of loading peptides corresponding to the C-terminal tail
sequences of the NR2A and NR2B subunits on NMDA receptor
triggered activation of SynGAP. Cells were pre-loaded with peptides as
described in materials and methods section prior to incubation with
either L-aspartate or APV as indicated. (A) Triggering NMDA
receptor activation with 100 lM aspartate in the presence of 3 lM
glycine and 100 lM free Ca2+. (B) Triggering NMDA receptor
activation with 5 lM APV in the absence of free Ca2+. Data shown
is representative of mean ± S.E.M values for n = 5 experiments
performed on independent cell culture batches. Panel inserts show
SynGAP immunoprecipitates representative of a batch of cells assayed.
Panel A: lane 1, unloaded and unstimulated cells; lane 2, stimulated
and unloaded cells; lane 3, stimulated and P1 loaded cells; lane 4,
stimulated and P2 loaded cells; lane 5, stimulated and P3 loaded cells;
lane 6, stimulated and P4 loaded cells. Panel B: lane 1, unloaded and
unstimulated cells; lane 2, stimulated and P1 loaded cells; lane 3,
stimulated and P2 loaded cells; lane 4, stimulated and P3 loaded cells;
lane 5, stimulated and P4 loaded cells; lane 6, stimulated and P5 loaded
cells.SynGAP pathway. Next, we looked at the eﬀect of tagged
peptides containing speciﬁc NR2 subunit sequences on the
NMDA receptor activation of SynGAP and interestingly
found that peptide P2 which contained the C-terminal amino
acid sequence of the NR2B subunit not only blocked the recep-
tor triggered activation, but in fact inhibited SynGAP activity
when compared to the basal (unstimulated) SynGAP activity
approximately two fold (Fig. 4A). Furthermore, peptide P3,
which corresponds to the C-terminal amino acid sequence of
the NR2A subunit, had no signiﬁcant eﬀect on the NMDA
receptor triggered activation of SynGAP (33 ± 7% stimula-
tion). Since both these peptides contain the ESDV motif, we
reasoned that the selective inhibitory eﬀect of the NR2B se-
quence may correspond to the unique YEKLSSI sequence
found in the NR2B but not the NR2A subunit C-terminal tail.
So we loaded cells with a peptide corresponding to this se-
quence (herein denoted peptide P4) and assessed its eﬀect on
NMDA receptor triggered activation of SynGAP . We found
that this peptide similarly inhibited the receptor triggered acti-
vation of SynGAP (150 ± 44%). From these data we conclude
ﬁrstly that the NR2B subunit and not the NR2A subunit selec-
tively couples to the (aspartate-mediated) NMDA receptor
triggered activation of SynGAP. In addition, this subunit
and SynGAP activation selectivity is conferred by the YEKLS-
SI sequence since both peptides P2 and P3 contained the
ESDV motif, but only peptide P2 disrupted the SynGAP acti-
vation. These ﬁndings are intriguing because very recently the
NR2B subunit of the NMDA receptor has been shown to
selectively associate with SynGAP and appears to be required
for inhibition of the NMDA receptor dependent Erk activa-
tion. This, in turn, correlates with the inhibition of the surface
expression of the GluR1 (AMPA) receptor [36]. Our ﬁndings
would be consistent with this subunit selectivity for SynGAP
and, since CaM kinase II is believed to be critical for GluR1
recruitment at the synapse, this would also agree with our ﬁnd-
ing of this CaM kinase II dependent mechanism being medi-
ated selectively via the NR2B receptor. Indeed, CaM kinase
II does bind directly to the NR2B subunit [37].
Next we probed the molecular mechanism involved in the
Ca2+, CaM kinase II independent SynGAP activation process
which we observed when triggering NMDA receptor activa-
tion with APV (Fig. 4B). Using the same peptide loading pro-
cedure as previously employed and triggering SynGAP
activation with APV (in the absence of extracellular Ca2+)
we ﬁrstly looked at the eﬀect of peptides P2 and P3 (corre-
sponding to the NR2B and NR2A subunit sequences, respec-
tively) and control peptide P1 on this process. We found that
both peptides P2 and P3, but not peptide P1 blocked SynGAP
activation, suggesting that this time the ESDV motif may be
important for this activation process. Using a peptide whose
sequence corresponded to the ESDV motif alone (peptide
P5) we observed the same blocking eﬀect, whereas the peptide
P4, which corresponded to the ‘‘YEKLSSI’’ NR2B speciﬁc se-
quence did not block the receptor activation of SynGAP.
From these data we conclude that the Ca2+/CaM kinase II-
independent receptor activation of SynGAP may not be
NR2B subunit selective and is mediated via a mechanism
which requires this ESDV sequence found in both NR2A
and B subunits.
In order to evaluate the eﬀect of these peptides on the PSD-
95, SynGAP and NR2B subunit co-association in our system,
we immunoprecipitated PSD-95 from peptide loaded cells
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found (in agreement with others using slightly longer C-termi-
nal peptides in brain slice experiments [35]) that peptides P2 and
P3 inhibited the PSD-95 co-association with NR2B subunits. In
addition, by using fragments of the NR2B tail sequence, we
found that peptide P5 was also suﬃcient to inhibit this interac-
tion whilst peptides P1 and P4 had no signiﬁcant eﬀect. From
these data we conclude that the APV-mediated stimulation of
SynGAP correlates well with the loss of PSD-95 interaction
with the NR2B subunit, but there is no correlation between
these proteins interacting and the ability of aspartate (via
CaM kinase II) to stimulate SynGAP activity. In addition,
SynGAP levels found associated with PSD-95 were not signif-
icantly found to alter with peptide treatments (Fig. 5).
Finally, we went on to look at whether AMPA and kainate
receptor activation could regulate SynGAP activity. Ras/
MAPK regulation is believed to play an important role in both
the AMPA receptor expression and the localisation/clustering
of receptors in the post synaptic membrane [36]. Hence,
cross-talk between post synaptic glutamate receptors could be
an important link in Ras regulation pathways. Therefore, we
activated both AMPA and kainate receptors with AMPA and
in the presence or absence of extracellular Ca2+ and looked
to see what eﬀect these treatments had on SynGAP activity
(Fig. 6). We found that AMPA treatment of cells whether in
the presence or absence of extracellular Ca2+inhibited SynGAP
activity (by 74 ± 8% and 44 ± 8%, respectively). However, we
consistently found that the presence of extracellular Ca2+ dur-
ing the AMPA treatment of cells reduced the inhibition of Syn-
GAP inhibition by approximately 30% (Fig. 6A).This
suggested that there may be an AMPA inhibitory mechanism
which was attenuated by a Ca2+-dependent stimulatory mech-
anism. We reasoned that the dependent Ca2+ mechanism could
be a Ca2+/CaM kinase II dependent eﬀect since AMPA and kai-
nate receptor activation would cause membrane depolarisation
which in turn could conceivably activate voltage operated Ca2+
channels to allow Ca2+ inﬂux. However, when we pre-treated
cells with KN-62 we found no signiﬁcant eﬀect on this Ca2+
mediated attenuation of SynGAP inhibition (data not shown).
Thus indicating that CaM kinase II plays no role in this Ca2+-
mediated event. Furthermore, when we looked at the eﬀect of
our control (peptide P1) or NR2 subunit peptides (P2 and
P3) on this Ca2+ and AMPA triggered inhibition of SynGAP
(Fig. 6B). We found that none of these peptides had any signif-
icant eﬀect on the Ca2+ mediated attenuation of the AMPA re-
sponse; indicating that this Ca2+ mediated mechanism was notFig. 5. Eﬀect of loading peptides corresponding to the C-terminal tail
sequences of the NR2A and NR2B subunits on the Co-immunopre-
cipitation of PSD-95, NR2B and SynGAP from cortical neurones.
Cells were pre-loaded with peptides as described in materials and
methods section. Cells were then lysed and incubated with anti-PSD-95
antibodies, followed by Western blot analysis probing for the presence
of PSD-95, SynGAP and NR2B subunits. Data shown is representa-
tive of n = 3 independent experiments performed.
Fig. 6. AMPA treatment inhibits SynGAP activity in cortical neuro-
nes. Adherent cells in culture were treated at 25 C for 5 min with 5 lM
AMPA in extracellular incubation buﬀer in the presence or absence of
100 lM free Ca2+ as indicated. After treatment, cells were lysed,
immunoprecipitated with anti-SynGAP antibodies and assayed for
Ras GAP activity as detailed in the methods section. (A) eﬀect of
extracellular Ca2+ on AMPA inhibition of SynGAP. (B) Pre-loading
cells with peptides has no eﬀect on the Ca2+ mediated relief of SynGAP
inhibition triggered by AMPA treatment. Data shown is representative
of mean ± S.E.M values for n = 3 experiments performed on indepen-
dent culture batches. Panel inserts show SynGAP immunoprecipitates
representative of a batch of cells assayed. Panel A: lane 1, untreated
cells; lane 2, AMPA stimulated  Ca2+; lane 3, AMPA stimu-
lated + Ca2+. Panel B: lane 1, AMPA stimulated  Ca2+; lane 2,
AMPA stimulated + Ca2+ and no peptide loaded; lane 3, AMPA
stimulated + Ca2+ and P1 loaded; lane 4, AMPA stimulated + Ca2+
and P2 loaded; lane 5, AMPA stimulated + Ca2+ and P3 loaded cells.
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activation of SynGAP.
From this study we conclude ﬁrstly, that APV is not a true
‘‘antagonist’’ of the NMDA receptor and, as such, studies using
this compound and assuming antagonistic biological function
may need some re-evaluation. Secondly, we have detected both
a Ca2+/CaM kinase II dependent and a Ca2+/CaM kinase II
independent (but PSD-95/NR2 subunit dependent) mechanism
for SynGAP stimulation. These data suggest that SynGAP
activity-dependent cellular eﬀects may not necessarily be re-
lated to PSD-95 interaction with the NR2B subunit. Instead,
the CaM kinase II dependent mechanism of SynGAP activa-
tion does not appear to be linked with the PSD-95/NR2B sub-
unit interaction but does appear to involve the ‘‘YEKLSSI’’
sequence in the NR2B subunit. The molecular components in-
volved in this mechanism require further elucidation.
In addition, it is also possible that speciﬁc isoforms of Syn-
GAP may exhibit diﬀerential mechanisms of signalling via
NMDA receptors. Such mechanisms, in turn, may be depen-
dent upon the stage of neuronal development and the expres-
sion levels of each molecular component in speciﬁc locations
within the brain. All of these possibilities can be further stud-
ied using this SynGAP assay system in combination with
immunoprecipitating antibodies recognising selective epitopes
found in speciﬁc SynGAP isoforms. Further work in this area
may lead to a better understanding of the physiological func-
tions of this protein.
Finally, since not only NMDA receptors but also AMPA/
kainate receptors appear to regulate SynGAP activity, it is
conceivable that the combination of the two events, (which
would be expected to occur upon glutamate release from
pre-synaptic sites) may serve to ﬁnely tune SynGAP activity.
Hence it may be subtle changes towards critical threshold lev-
els which in turn result in MAPK-dependent eﬀects leading to
synaptic plasticity events.
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